Drug Profile
Research programme: multiple sclerosis therapies - Selecore
Latest Information Update: 18 May 2011
Price :
$50
*
At a glance
- Originator Selecore
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 07 Sep 2005 Preclinical trials in Autoimmune disorders in Germany (PO)